These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25823738)

  • 1. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
    Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
    J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
    Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
    Clin Cancer Res; 2013 Dec; 19(23):6624-32. PubMed ID: 24130072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.
    Ng K; Sargent DJ; Goldberg RM; Meyerhardt JA; Green EM; Pitot HC; Hollis BW; Pollak MN; Fuchs CS
    J Clin Oncol; 2011 Apr; 29(12):1599-606. PubMed ID: 21422438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
    Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
    Cancer; 2014 Jun; 120(12):1830-7. PubMed ID: 24668580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
    Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
    J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
    Chen CS; Zirpoli G; Barlow WE; Budd GT; McKiver B; Pusztai L; Hortobagyi GN; Albain KS; Damaj MI; Godwin AK; Thompson A; Henry NL; Ambrosone CB; Stringer KA; Hertz DL
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1172-1180.e3. PubMed ID: 37935109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
    Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
    Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inherited genetic variation and overall survival following follicular lymphoma.
    Gibson TM; Wang SS; Cerhan JR; Maurer MJ; Hartge P; Habermann TM; Davis S; Cozen W; Lynch CF; Severson RK; Rothman N; Chanock SJ; Morton LM
    Am J Hematol; 2012 Jul; 87(7):724-6. PubMed ID: 22473939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital and manual interfollicular Ki-67 are associated with a progression-free survival in patients with low-grade follicular lymphoma.
    Nasir A; Hegerova L; Yousaf H; Forster CL; Shanley R; Linden MA; Bachanova V; Yohe S
    Am J Clin Pathol; 2024 Apr; 161(4):380-387. PubMed ID: 38044670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular lymphoma polygenic risk score is associated with increased disease risk but improved overall survival among women in a population based case-control in Los Angeles County California.
    Zhong C; Chao CR; Song JY; Weisenburger DD; Luo J; Ding YC; Neuhausen SL; Bernstein L; Cozen W; Wang SS
    Cancer Epidemiol; 2020 Apr; 65():101688. PubMed ID: 32092486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.
    Cerhan JR; Wang S; Maurer MJ; Ansell SM; Geyer SM; Cozen W; Morton LM; Davis S; Severson RK; Rothman N; Lynch CF; Wacholder S; Chanock SJ; Habermann TM; Hartge P
    Blood; 2007 Jun; 109(12):5439-46. PubMed ID: 17327408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Milrod CJ; Kim KW; Raker C; Ollila TA; Olszewski AJ; Pelcovits A
    Br J Haematol; 2024 Jun; 204(6):2237-2241. PubMed ID: 38571449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
    Wang QL; Ma C; Yuan C; Shi Q; Wolpin BM; Zhang Y; Fuchs CS; Meyer J; Zemla T; Cheng E; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Kumar P; Tan B; Krishnamurthi S; Goldberg RM; Venook A; Blanke C; Shields AF; O'Reilly EM; Meyerhardt JA; Ng K
    Clin Cancer Res; 2023 Jul; 29(14):2621-2630. PubMed ID: 37289007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in follicular lymphoma: choosing the best target.
    Sehn LH
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):284-292. PubMed ID: 27913493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018.
    Dinnessen MAW; Visser O; Tonino SH; Posthuma EFM; Blijlevens NMA; Kersten MJ; Lugtenburg PJ; Dinmohamed AG
    Blood Cancer J; 2021 Nov; 11(11):179. PubMed ID: 34775466
    [No Abstract]   [Full Text] [Related]  

  • 16. Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735-3738.
    Blood Adv; 2024 Jun; 8(12):3225. PubMed ID: 38874949
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
    Al Tabaa Y; Casasnovas RO; Baillet C; Bachy E; Nicolas-Virelizier E; Schiano De Colella JM; Bailly C; Kanoun S; Guidez S; Gyan E; Gressin R; Morineau N; Ysebaert L; Le Gouill S; Tilly H; Houot R; Morschhauser F; Cartron G; Herbaux C
    Blood Adv; 2023 Jul; 7(14):3735-3738. PubMed ID: 37067945
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.
    Bruns H; Büttner M; Fabri M; Mougiakakos D; Bittenbring JT; Hoffmann MH; Beier F; Pasemann S; Jitschin R; Hofmann AD; Neumann F; Daniel C; Maurberger A; Kempkes B; Amann K; Mackensen A; Gerbitz A
    Sci Transl Med; 2015 Apr; 7(282):282ra47. PubMed ID: 25855493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
    Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
    Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.